Latest Breakthrough seizure Stories
AZ-002 Phase 2a Study in Patients with Epilepsy Planned for Second Half of 2014 MOUNTAIN VIEW, Calif., July 31, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc.
The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy.
A new drug could provide hope for people who suffer from epileptic seizures.
WASHINGTON, May 12 /PRNewswire/ -- The Epilepsy Foundation recently announced findings that show people with epilepsy, whose seizures have been controlled with a consistent drug therapy, have a greater chance of increased seizures, greater side effects or sudden death when their medications are switched from one version of an antiepileptic drug (AED) to another, whether the switch was brand-to-generic, generic-to-brand or generic-to-generic. See video from the Epilepsy Foundation at:...
A new study reveals it is generally safe to stop anti-seizure medications in children with epilepsy who have been seizure-free while on the treatment.
Valeant Pharmaceuticals, a specialty pharmaceutical company, has signed an agreement with GlaxoSmithKline for the promotion of Diastat and Diastat AcuDial, the first and only FDA-approved, acute at-home medication for patients two years and older on stable antiepileptic medications who experience bouts of increased seizure activity, sometimes called serial or cluster seizures or breakthrough seizures.
Valeant Pharmaceuticals (NYSE:VRX) today announced that it has signed an agreement with GlaxoSmithKline (NYSE:GSK) for the promotion of Diastat(R) and Diastat(R) AcuDial(TM), the first and only FDA-approved, acute at-home medication for patients two years and older on stable antiepileptic medications (AEDs) who experience bouts of increased seizure activity, sometimes called serial or cluster seizures or breakthrough seizures.
- The act of sweetening by admixture of some saccharine substance.